The dynamic changes of zinc transporter 8 autoantibodies in Czech children from the onset of Type 1 diabetes mellitus

Diabetic Medicine

Volumn 31, Issue 2, 2014, Pages 165-171

  Petruzelkova, L ^a   Ananieva Jordanova, R ^b   Vcelakova, J ^a   Vesely, Z ^a   Stechova, K ^a   Lebl, J ^a   Dusatkova, P ^a   Sumnik, Z ^a   Coles, R ^b   Powell, M ^b   Furmaniak, J ^b   Rees Smith, B ^b   Kolouskova, S ^a  

^a UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^b RSR LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; AUTOANTIBODY; GLUTAMATE DECARBOXYLASE; INSULIN; INSULINOMA ANTIGEN 2; UNCLASSIFIED DRUG; ZINC TRANSPORTER; ZINC TRANSPORTER 8; CATION TRANSPORT PROTEIN; SLC30A8 PROTEIN, HUMAN;

ADOLESCENT; ADULT; ARTICLE; BLOOD SAMPLING; CHILD; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FAMILY HISTORY; FEMALE; FOLLOW UP; GEL PERMEATION CHROMATOGRAPHY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MOLECULAR DYNAMICS; ONSET AGE; PREDICTIVE VALUE; PRESCHOOL CHILD; RADIOIMMUNOASSAY; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; YOUNG ADULT; BLOOD; CASE CONTROL STUDY; CZECH REPUBLIC; DIABETES MELLITUS, TYPE 1; IMMUNOLOGY; INFANT; TIME;

ADOLESCENT; AGE OF ONSET; AUTOANTIBODIES; CASE-CONTROL STUDIES; CATION TRANSPORT PROTEINS; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; CZECH REPUBLIC; DIABETES MELLITUS, TYPE 1; HUMANS; INFANT; SEROEPIDEMIOLOGIC STUDIES; TIME FACTORS; YOUNG ADULT;

EID: 84892559986     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12308     Document Type: Article

References (28)

1. Wenzlau JM, Juhl K, Yu L, Moua O, Sarkar SA, Gottlieb P et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci U S A 2007; 104: 17040-17045.
2. Chimienti F, Devergnas S, Favier A, Seve M. Identification and cloning of a β-cell-specific zinc transporter, ZnT-8, localized into insulin secretory granules. Diabetes 2004; 53: 2330-2337.
3. Wenzlau JM, Moua O, Sarkar SA, Yu L, Rewers M, Eisenbarth GS et al. SlC30A8 is a major target of humoral autoimmunity in type 1 diabetes. Ann N Y Acad Sci 2008; 1150: 256-259.
4. Wenzlau JM, Frisch LM, Gardner TJ, Sarkar S, Hutton JC, Davidson HW. Novel antigens in type 1 diabetes: the importance of ZnT8. Curr Diab Rep 2009; 9: 105-112.
5. Andersson C, Larsson K, Vaziri-Sani F, Lynch K, Carlsson A, Cedervall E et al. The three ZNT8 autoantibody variants together improve the diagnostic sensitivity of childhood and adolescent type 1 diabetes. Autoimmunity 2011; 44: 394-405.
6. Vermeulen I, Weets I, Asanghanwa M, Ruige J, Van Gaal L, Mathieu C et al. Contribution of antibodies against IA-2β and zinc transporter 8 to classification of diabetes diagnosed under 40 years of age. Diabetes Care 2011; 34: 1760-1765.
7. Vaziri-Sani F, Oak S, Radtke J, Lernmark K, Lynch K, Agardh CD et al. ZnT8 autoantibody titres in type 1 diabetes patients decline rapidly after clinical onset. Autoimmunity 2010; 43: 598-606.
8. Wenzlau JM, Walter M, Gardner TJ, Frisch LM, Yu L, Eisenbarth GS et al. Kinetics of the post-onset decline in zinc transporter 8 autoantibodies in type 1 diabetic human subjects. J Clin Endocrinol Metab 2010; 95: 4712-4719.
9. Wenzlau JM, Liu Y, Yu L, Moua O, Fowler KT, Rangasamy S et al. A common non-synonymous single nucleotide polymorphism in the SLC30A8 gene determines ZnT8 autoantibody specificity in type 1 diabetes. Diabetes 2008; 57: 2693-2697.
10. Lampasona V, Schlosser M, Mueller PW, Williams AJ, Wenzlau JM, Hutton JC et al. Diabetes antibody standardization program: first proficiency evaluation of assays for autoantibodies to zinc transporter 8. Clin Chem 2011; 57: 1693-1702.
11. Craig ME, Hattersley A, Donaghue KC. Definition, epidemiology and classification of diabetes in children and adolescents. Pediatr Diabetes 2009; 10: 3-12.
12. 125I-labelled recombinant GAD65 produced in yeast. Clin Chim Acta 1996; 256: 175-188.
13. Masuda M, Powell M, Chen S, Beer C, Fichna P, Rees Smith B et al. Autoantibodies to IA-2 in IDDM measurements with a new immunoprecipitation assay. Clin Chim Acta 2000; 291: 53-66.
14. Törn C, Mueller PW, Schlosser M, Bonifacio E, Bingley PJ, Participating Laboratories. Diabetes Antibody Standardization Program: evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2. Diabetologia 2008; 51: 846-852.
15. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993; 39: 561-577.
16. Powell M, Ananieva-Jordanova R, Brooking H, Amoroso M, Chlebowska M, Niemier N et al. A sensitive and specific non-isotopic assay for the measurement of autoantibodies to zinc transporter 8. 11th International Congress of the Immunology of Diabetes Society, Incheon, South Korea, 31 Oct-3 Nov 2010
17. Vaziri-Sani F, Delli AJ, Elding-Larsson H, Lindblad B, Carlsson A, Forsander G et al. A novel triple mix radiobinding assay for the three ZnT8 (ZnT8-RWQ) autoantibody variants in children with newly diagnosed diabetes. J Immunol Meth 2011; 371: 25-37.
18. Achenbach P, Lampasona V, Landherr U, Koczwara K, Krause S, Grallert H et al. Autoantibodies to zinc transporter 8 and SLC30A8 genotype stratify type 1 diabetes risk. Diabetologia 2009; 52: 1881-1888.
19. Hameed S, Ellard S, Woodhead HJ, Neville KA, Walker JL, Graig ME et al. Persistently autoantibody negative (PAN) type 1 diabetes mellitus in children. Pediatr Diabetes 2011; 12: 142-149.
20. Kordonouri O, Hartmann R, Deiss D, Wilms M, Grüters-Kieslich A. Natural course of autoimmune thyroiditis in type 1 diabetes: association with gender, age, diabetes duration, and puberty. Arch Dis Child 2005; 90: 411-414.
21. Wasmeier C, Hutton J. Molecular cloning of phogrin, a protein-tyrosine phosphatase homologue localized to insulin secretory granule membranes. J Biol Chem 1996; 271: 18161-18170.
22. Achenbach P, Bonifacio E, Koczwara K, Ziegler AG. Natural history of type 1 diabetes. Diabetes 2005; 54: S25-S31.
23. De Grijse J, Asanghanwa M, Nouthe B, Albrecher N, Goubert P, Vermeulen I et al. Predictive power of screening for antibodies against insulinoma-associated protein 2β (IA-2β) and zinc transporter-8 to select first-degree relatives of type 1 diabetic patients with risk of rapid progression to clinical onset of the disease: implications for prevention trials. Diabetologia 2010; 53: 517-524.
24. Savola K, Sabbah E, Kulmala P, Vähäsalo P, Ilonen J, Knip M. Autoantibodies associated with Type I diabetes mellitus persist after diagnosis in children. Diabetologia 1998; 41: 1293-1297.
25. Decochez K, Tits J, Coolens JL, Van Gaal L, Krzentowski G, Winnock F et al. High frequency of persisting or increasing islet-specific autoantibody levels after diagnosis of type 1 diabetes presenting before 40 years of age. The Belgian Diabetes Registry. Diabetes Care 2000; 23: 838-844.
26. Borg H, Gottsäter A, Fernlund P, Sundkvist G. A 12-year prospective study of the relationship between islet antibodies and β-cell function at and after the diagnosis in patients with adult-onset diabetes. Diabetes 2002; 51: 1754-1762.
27. Bonifacio E, Bingley PJ, Shattock M, Dean BM, Dunger D, Gale EA et al. Quantification of islet-cell antibodies and prediction of insulin-dependent diabetes. Lancet 1990; 335: 147-149.
28. Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001; 358: 221-229.